The Role of Hormone Replacement Therapy (HRT) and Tibolone in the Prevention and Treatment of Postmenopausal Osteoporosis by Marta Lamarca
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
29 
The Role of Hormone Replacement Therapy 
(HRT) and Tibolone in the Prevention and 
Treatment of Postmenopausal Osteoporosis 
Marta Lamarca 
Department of Gynecology,  
Miguel Servet University Hospital, Zaragoza, 
Spain 
1. Introduction 
Life expectancy has increased considerably in recent decades thanks to the improvement of 
measures for health protection and disease prevention as well as improvements in the 
quality of health systems. While in the middle of last century the average life expectancy of 
a woman was about 50 years, today there are over 350 million women older than 60. 
Furthermore, from the perspective of developed countries, postmenopause is a stage that 
spans more than one third of the life of a woman. That is why the research on the 
pathophysiology and treatment of menopause has become necessary and important. 
The decrease in sex steroid production by the ovary that occurs in perimenopause and 
menopause is associated with a rapid loss of bone mass due to increased resorption. In the 
past two decades, multiple observational studies have noted the beneficial effect of hormone 
replacement therapy (HRT) in postmenopausal women's health, based mainly on the relief 
of symptoms associated with estrogen deprivation such as vasomotor and genitourinary 
symptoms. These studies also indicated a preventive effect on aging-related diseases such as 
osteoporosis. Estrogens have been shown to be effective in increasing bone mineral density 
(BMD) and prevent fractures, but information on side effects from long use has reduced 
their use for the treatment of osteoporosis (Tamborini & Ruiz, 2004).  
Tibolone is a synthetic steroid used in the treatment of postmenopausal symptoms and 
decreased libido that has an estrogen agonist effect on bone.  
Although the intimate mechanisms of control of bone remodelling are not still completely 
known, we do have enough information to say that estrogens have a role in the homeostasis 
of the skeleton, which is why their decline is associated with reduced bone mass, impaired 
in the microarchitecture and increased risk of fracture. 
The following chapter discusses the role of estrogen therapy and tibolone in the prevention 
and treatment of postmenopausal osteoporosis. 
2. Literature search 
Studies with English language abstracts identified in MEDLINE, HealthSTAR, and 
Cochrane Library databases from 1990 to 2010 are reviewed. Reference lists of key articles 
www.intechopen.com
 
Osteoporosis 
 
610 
and meta-analyses have also been reviewed. We used all published studies of HRT and 
tibolone if they contained a comparison group of HRT nonusers and reported data relating 
to HRT use and clinical outcomes of interest. Studies have been excluded if the population 
was selected according to prior events or presence of conditions associated with higher risks 
for targeted outcomes. 
3. Hormone replacement therapy (HRT) 
3.1 Effect of sex steroids on bone 
The possible adverse effects of estrogen deficiency on the bone metabolism are known since 
the 40 decade (Albright, 1940, 1947). The first studies confirmed a higher rate of 
oophorectomies among osteoporotic women than in general population, and that the 
surgical treatment had place earlier than the age for natural menopause. These studies also 
showed that the negative balance of osteoporosis was normalized with the administration of 
estrogen. Thus it was postulated that estrogen somehow stimulated the action of osteoblasts, 
which is now accepted as one of the potential mechanisms of action of estrogen on bone 
mass (Lindsay, 1995). 
Oophorectomized and postmenopausal women have decreased circulating levels of other 
steroids in addition to estrogens (Lindsay, 1995). In women, circulating androgen 
concentrations are in the order of nanomoles or micromoles while estrogens do so at 
concentrations on the order of picomoles. The concept of androgen deficiency syndrome is 
relatively old, but in recent years there has been a renewed interest in the subject. 
The premenopausal ovary produces significant amounts of progesterone during the luteal 
phase of each cycle. Progesterone appears to act directly on bone turnover and may play a 
role in the relationship between bone resorption and new bone formation (Prior, 1990). 
Although we do not yet fully understand the bone turnover process or control, there is 
sufficient information to conclude that sex steroids play an important role in skeletal 
homeostasis. The lack of secretion of ovarian sex steroids results in a net loss of bone tissue. 
When given to women with deficiency of sex steroids, these hormones reverse many of the 
effects related to loss of ovarian function. Therefore, it has been suggested that 
postmenopausal women should take HRT long term to prevent these negative effects, 
including osteoporosis and fractures. 
3.1.1 Estrogens and bone 
With the decrease in estrogen levels that occurs at menopause, there is an increase of bone 
remodelling with a loss of balance between formation/resorption, predominantly the latter. 
HRT decreases the elevated levels of resorption to those before menopause. Bone cells have 
estrogen receptors (Vidal et al., 1999). The most important action of estrogen on bone is to 
inhibit bone resorption. This action indirectly regulates the production of cytokines and 
growth factors in osteoblasts. Since there are estrogen receptors in osteoclasts, may also be 
logical to think that there is a direct action. Inhibition of bone resorption by estrogen is 
probably the conclusion of inducing apoptosis in osteoclasts (Kameda et al., 1997), this 
action being probably due to increased TGF-┚. Estrogens have shown to increase the 
proliferation of osteoblasts and the expression of different genes that encode enzymes, bone 
matrix proteins, transcription factors, hormone receptors, growth factors and cytokines. 
However, these results have varied depending on crop models (Manolagas, 2000). Estrogens 
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have also shown the ability to inhibit TRAP expression or inhibit certain steps in the RANK-
JNK signal (Srivastava et al., 2001). 
The current idea of the action of estrogen is that it is through different pathways. There is, 
first, an antiapoptotic effect of estradiol on osteoblasts and osteocytes due to rapid non-
genomic action (Kousteni et al., 2001). It has succeeded in synthesizing a ligand called 
ESTREN that act exclusively through this channel, and theoretically could have the same 
effect as estrogens on bone without the genomic consequences of these. This model has been 
named to a new class of pharmacological agents called ANGELS (Activators of 
NonGenotropics Estrogens Like Signalins), and there would be another apoptotic action on 
osteoclasts (Manolagas et al., 1995). The actions of estrogen on bone cells, are inhibition of 
bone resorption by decreasing the synthesis or response to interleukins such as IL-6, IL-1 
and TNF-┙ with less differentiation of precursor cells into osteoclasts by increasing IL-4. 
Among other effects, estrogens decrease lytic enzyme activity of osteoclasts and produce 
changes in growth factors insulin-like IGF-I, IGF-II and interferon types ┙, ┚ and ┛. The 
effect of estrogen is mediated in part by growth factors and interleukins such as IL-6, which 
is a potent stimulator of bone resorption by blocking estrogen synthesis by osteoblasts. 
Estrogen may also antagonize the interleukin receptors. The apoptosis of osteoclasts is also 
regulated by estrogens. Faced with reduced levels of estrogen, osteoclasts live longer and 
have greater capacity of absorption. Estrogens regulate tumor growth factor system 
associated with the RANK/RANK-L resulting in a decrease in the activity of osteoclasts. 
They also stimulate the production of osteoprotegerin (OPG) by osteoblasts. Thus, the 
presence of estrogen prevents binding of RANK-L to RANK resulting in inhibition of the 
formation, differentiation and survival of osteoclasts (Eghbali-Fatourechi et al., 2003). In 
response to increased bone resorption, it exists an increase in bone formation, creating a 
high turnover that leads to bone loss and deterioration in the microarchitecture. In the first 5 
years since menopause, a substantial disruption of the trabecular architecture can be 
observed, demonstrated by the analysis of iliac crest biopsies using computed 
microtomography techniques (Issever et al., 2002). Once broken the continuity of a 
trabecula, we can increase thickness, but will not get a new connectivity. 
We could conclude that steroid hormones are involved with a complex action system clearly 
influencing the bone marrow regulation. They are part of the mechanism regulating RANK-
RANKL-osteoprotegerin, whose predominant action is bone resorption, and it is performed 
through genomic and nongenomic actions. In addition, estrogens also act through indirect 
mechanisms of action such as reducing the sensitivity of the bone to resorptive effects of 
parathyroid hormone (PTH), acting as antiresorptive agents. They produce an initial 
decrease in serum calcium and, therefore, a transient increase in PTH and calcitonin 
secondary modifications. Due to the increase in ┙ 1-hydroxylase activity and phosphorus 
decreased, they produce an increase in hydroxyvitamin D3. Estrogens also increase the 
intestinal absorption and decrease renal excretion of calcium, and have direct effects on the 
secretion of PTH and calcitonin. 
3.1.2 Androgens and bone 
Androgens have a profound effect on bone and muscle physiology in women. Both for their 
intrinsic activity as for their conversion to estrogens, androgens have a modulatory effect on 
bone remodelling cycle. The androgen deficiency, like estrogen, may facilitate the 
development of osteoporosis. Androgenic anabolic steroids are sometimes used in the 
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treatment of osteoporosis but their use is limited by side effects of virilizing type. Evidence 
of the effects of androgens on bone mass comes from women with polycystic ovary 
syndrome or steroid-secreting ovarian tumors in which there is an increase in bone mineral 
density (Gregoriou et al., 2000). On the other hand, we know that the combination of 
androgens and estrogens for hormone replacement therapy in menopausal women is 
associated with increased bone mass above that observed with estrogen alone (Castelo-
Branco et al., 2000). A cohort study developed to assess BMD in postmenopausal women 
using estradiol and testosterone hormonal implants comparing to that of patients without 
hormonal therapy, confirmed that BMD variance between the groups in the period of 1 year 
was significantly different, and concluded that the combination of estradiol and testosterone 
promoted bone protection in postmenopausal women (Britto et al., 2011). 
Androgen receptors have been identified in osteoblasts, osteoclasts and osteocytes. 
Androgens stimulate the proliferation and differentiation of osteoblasts, stimulate the 
synthesis of extracellular matrix proteins, and stimulate mineralization. These steroids affect 
the functionality of bone cells through their effects on local factors that control bone cell 
microenvironment, have proapoptotic effects on osteoblasts and osteocytes, and increase 
strength and muscle. This ultimately leads to increased physical activity and this in turn to 
activation of bone formation by stimulation of the osteocytes (Notelovitz, 2002). 
3.1.3 Progestins and bone 
The role of progestins in preventing bone loss is less studied. However, there is general 
consensus that 19-norderived progestins with androgenic properties, such as norethindrone 
and norethindrone acetate, at higher doses than necessary for hormone replacement 
therapy, have beneficial effects on bone density. 
Thus, for example, progestins can increase bone density in women with postmenopausal 
osteoporosis and alleviate the effects of estrogen deficiency in young women treated with 
GnRH agonists. However, data on the effects of progestins C21 derivatives such as 
medroxyprogesterone acetate are mixed. It has been reported that, in premenopausal 
women with luteal defects, medroxyprogesterone acetate (10mg/day, 10 days/cycle) can 
significantly increase vertebral bone density (Prior et al., 1994). In contrast, administration of 
20 mg/day of this progestin could not stop the loss of vertebral bone density in 
postmenopausal women (Gallagher et al., 1991). In addition, premenopausal women using 
depot medroxyprogesterone acetate as a contraceptive or taking oral doses (50mg/day) of 
this progestin on gynecologic pathology have varying significantly decreased bone density 
(Cundy et al., 1996). The different findings in these studies clearly indicate that the effects of 
medroxyprogesterone acetate on bone may vary according to the dose administered and the 
estrogen status of the user. When administered in doses sufficient to induce hypogonadism, 
medroxyprogesterone acetate is associated with a rapid and significant loss of bone mineral 
density at the lumbar level. This bone loss is the result of estrogen deficiency and occurs 
despite an increase in body weight, although it seems partially reversible. 
Clinical trials have shown that postmenopausal women receiving norethindrone acetate 
associated with estrogen show a significant increase in bone mineral density compared with 
patients treated only with estrogen (Speroff et al., 1996). In contrast, neither the micronized 
progesterone nor medroxyprogesterone acetate contributed significantly to the positive 
effects of estrogen on bone (PEPI Trial, 1996). 
Progestins influence the bone formation within the bone remodelling process (Sootweg et 
al., 1992). Receptors for progesterone have been identified in human osteoblasts and 
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osteoclasts. However, the effects of progestagens on bone are not clear. A study about the 
activity of a "pure progestogen" on human osteogenic osteosarcoma cells did not observe 
any effect on cell proliferation when progestins were added alone to culture, but after the 
combined administration with 17┚-estradiol, a strong action synergistically was confirmed 
on the proliferation of osteosarcoma cells. Moreover, other studies show that some synthetic 
progestins produce their effects through the activation of the estrogen receptor (Jordan et al., 
1993). 
3.2 HRT - Type, dose 
Almost all information about the effects of estrogens on the bone come from the use of 
estradiol and conjugated equine estrogens (CEE). Isolated estrone also has a beneficial effect 
on bone, and it seems that estriol does not have an obvious role in skeletal production in 
postmenopausal women. 
The route of administration, oral or transdermal, does not imply differences in the beneficial 
effect on bone (Hillard et al., 1994). The estrogenic pulsotherapy has also shown a 
normalization of the markers of resorption and formation to premenopausal values after 3 
months of treatment at doses of 300 mcg/day. The increase in BMD at this dose is similar to 
that found with 50 mcg/day of transdermal 17-beta-estradiol, providing significant 
differences in the measurement of BMD over baseline in spine and hip in the evaluation 
performed after 56 weeks treatment (Palacios et al., 2002). In women with uterus is 
necessary to administer a progestin to counteract endometrial proliferation induced by 
estrogen. The dosing regimen of progestin does not influence the beneficial effect of 
estrogen on the bone so the choice is given by the characteristics of women. 
Significant BMD improvements have also been noted with systemic estrogen doses 
delivered via a vaginal ring. In an randomized controlled trial of 174 postmenopausal 
women younger than age 65, daily doses of 0.05 and 0.1 mg of estradiol acetate delivered via 
the ring significantly increased hip BMD (1.7% and 1.8%, respectively) and lumbar spine 
BMD (2.7% and 3.3%) compared with baseline (Al-Azzawi et al., 2005). 
It has been established that a dose range of estradiol between 40 and 50 pg/ml is enough to 
increase BMD, although a safe level is 60 pg/ml. A dose-response study indicated that daily 
doses would have more generalizable effect: 0.625 mg of conjugated equine estrogens (CEE), 
or their equivalents: 0.05 mg of transdermal 17-beta-estradiol or 15 mcg of oral ethinyl 
estradiol (EE). The standard dose preserves bone mass in at least 80% of postmenopausal 
women (Table 1). These doses of estrogen and progestogen can induce side effects in both 
regimes (continuous and sequential), being the most frequent irregular bleeding and breast 
tenderness. To minimize these undesirable effects, the use of low doses has shown to be also 
effective in improving menopausal symptoms and quality of life and prevent or reverse 
bone loss in postmenopausal women (Delmas et al., 2000). 
The loss of bone mass and the incidence of vertebral and hip fractures are inversely related 
to circulating estrogen levels. It has been confirmed that in elderly women estrogen 
circulating levels of 10 pg/ml improves both BMD and fracture rate. Any increase in 
estrogen levels has a beneficial effect especially in older women, even when the ultra-low 
dose is given (25% of the standard dose) (Simon & Snabe, 2007). Neither age nor initial BMD 
do seem to affect the effectiveness of patterns of low-dose. The effect of low doses of 
estrogen in women with low BMD has been analized in a randomized, double-blind, 
placebo-controlled trial, using CEE 0.3 mg/day and 2.5 mg/day of progesterone in women 
over 65 years and low BMD, in which after 3.5 years of follow up, an increase in vertebral 
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BMD of 5% and 1.6% in hip has been confirmed, with significant increase in total skeletal 
and forearm (Recker et al., 1999). 
 
 Low dose Standard dose  High dose 
Estradiol valerate 1 mg 2 mg 3 mg 
Transdermal 
Estradiol  
25-37,5 mcg 50 mcg 75-100 mcg 
CEE 0,3 mg 0,625 mg 1,25 mg 
Estrogen 
pulsotherapy 
 300 mcg  
Tibolone 1,25 mg 2,5 mg  
Table 1. Estrogen dose used in HRT 
The HOPE study (Women's Health Osteoporosis Progestin Estrogen) (Lindsay et al., 2005), 
evaluates the effectiveness of low and moderate doses, 0.45 mg/day and 0.30 mg/day alone 
or combined CEE on vasomotor symptoms, genital atrophy, metabolism, endometrial 
response and bone density in 2805 women aged 40-65 years treated for 2 years. The results 
confirmed an improvement in vasomotor symptoms and genital atrophy with low doses 
comparable to improvement obtained with standard doses, with less bleeding and the 
beneficial effect on lipid profile. Bone turnover markers such as osteocalcin and N-
telopeptide of type I collagen were significantly reduced compared to baseline in the 
treatment group while no changes were found in the placebo group. BMD increased in both 
vertebral and hip evaluation. Another study showed similar results (Gambacciani et al., 
2001), suggesting that low doses of HRT were able to reduce climacteric symptoms resulting 
in a decrease in bone turnover and protect against bone loss. The same study showed 
significant increases in BMD of 2.72 ± 0.3% in women treated while not receiving estrogen 
therapy had a loss in BMD of 7.9 ± 0.8%. 
In an open trial healthy postmenopausal women received for 2 years a low-dose continuous 
combined HRT containing 1mg estradiol plus 0.5 mg norethisterone acetate, or 0.5 mg of 17-
estradiol and 0.25 mg of norethisterone acetate (ultra low dose) along with 1000 mg of 
calcium per day. The study confirmed that low-dose-HRT and Ultra-low-dose-HRT can 
alleviate subjective symptoms providing an effective protection against the postmenopausal 
decrease of BMD (Gambacciani et al., 2008). 
Despite the large amount of literature about the beneficial effect of low doses in the bone, 
there are no studies linking low doses of HRT to the prevention of fractures.  
3.3 HRT limitations  
Women who may benefit from HRT are those showing climacteric symptoms and also 
osteoporosis risk. There is general consensus with regard to women with premature 
menopause should be treated until at least the theoretical age of menopause. 
At present there are few absolute contraindications to HRT, being as such pregnancy, 
vaginal bleeding not studied, active hepatitis, active venous thromboembolism and 
hormone-specific cancer history. 
However, there are circumstances that require careful consideration and consensus with the 
patient and the presence of pathological conditions such as lupus or endometriosis. Women 
treated with thyroid hormones or coumarin may need a dose adjustment. 
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3.4 Duration of HRT 
The reduction of bone loss will last as long as you keep the estrogen therapy. When you 
cease treatment, bone loss returns to pretreatment rate, therefore, to obtain maximum 
benefit, treatment should begin as early after menopause and stay as long as possible. The 
optimal duration of treatment has not been fully established, but the results from the 
Women's Health Inititative (WHI) suggest that estrogen therapy should take the lowest dose 
for the shortest possible time but then we know that short treatment will not positively 
affect bone mass. 
Analyzing the evolution of bone mass in climacteric women, it has been shown that during 
the 5 years after the time of onset of menopause the bone loss is equivalent to 60% of what is 
lost along the climacteric stage; it is at this time when occur the disruption of the trabecular 
architecture. Once the trabeculae are broken, they will not reconnect again, which would 
lose bone strength despite getting increases in BMD. Thus, estrogen therapy, at least 
theoretically, should start as early and stay at least that long in women with natural 
menopause and up to 55 years in women with early menopause. This would ensure that the 
loss of bone mass will be delayed, and it will have a positive impact on the possibility of 
developing osteoporosis and hence on the quality of life. 
The use of combined HRT has been associated with an increased risk of venous 
thromboembolism or coronary artery disease (after a year of use), acute stroke (after 3 years 
of use), breast cancer (after 5 years of use) and gallbladder disease. Long use of estrogen 
alone was associated with increased stroke and gallbladder disease. According to recent re-
analysis, age is a determining factor in establishing the risks, resulting in very young 
women (50-59 years) a very low absolute risk (Farquhar et al., 2005). 
However, even if treatment is started long after menopause, there are substantial gains in 
bone mass. In the Framingham study, elderly women with a mean age of 76 years and 7 
years since menopause had a significant increase in BMD compared to nonusers, although 
the effect was less marked in women over 75 years (Felson et al., 1993). 
3.5 Estrogen and progestogen combined treatment  
The association of progestin does not counteract the beneficial effect of estrogen on bone. It 
has been reported that derivatives of 19-norethisterone are effective in preventing bone loss 
even when associated with low estrogen dose (Christiansen & Riis, 1990). 
Some studies suggest a greater benefit by associating progestin, while others have failed to 
show this superiority to estrogen alone. It is possible that the effect has to do with the type 
of progestin used and it seems that this superior effect is limited exclusively to the 
administration of compounds of the family of 19-norethisterone. The Postmenopausal 
Estrogen/Progestin Interventions (PEPI) Trial, multicenter randomized controlled trial of 
875 postmenopausal women with an average age of 56 years, which after 3 years of follow-
up BMD increases are seen in lumbar spine (3-5%) and hip (1.7%) with no differences 
between groups treated with estrogen alone or combined with progestin (The Writing 
Group of the PEPI Trial, 1996). 
The BMD status before the start of hormonal treatment will not influence the effect of it. It 
has been shown that estrogen administered with and without progestin increases bone mass 
in healthy women as well and even in osteopenic women with osteoporosis and fractures 
(established osteoporosis) (Adachi et al., 1997). 
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3.6 Estrogen effect on BMD 
Estrogen administration, associated or not with progestin, has been shown highly effective 
in the prevention of bone loss in both natural and surgical menopause. It has been shown 
how treatment with estrogen and progestin can not only maintain but also increase BMD in 
postmenopausal women, compared to the decline experienced by the placebo group 
(Christiansen et al., 1981). More than 50 randomized, placebo-controlled studies have shown 
that estrogen alone or combined with progestin increases BMD, with values ranging from 4-
6% in spine and 2-3% in hip, justifying the difference by the different rate of remodelling of 
these places (Wells et al., 2002). 
Estrogen therapy also appears to be effective in patients with established osteoporosis. 
Women with low bone mass generally have higher turnover and this turnover increases 
with age. So the best response to estrogen observed in older women or in women with low 
BMD might result from the suppression of increased bone turnover associated with 
improvement in the bioavailability of calcium due to improved intestinal absorption of 
vitamin D. Using CEE double dose (1.2 mg/day) for one year, a double-blind, placebo-
controlled study in 21 osteoporotic women showed an improvement in BMD, more marked 
in the lumbar spine than in femoral neck and an increase in intestinal absorption of calcium 
(Citivelli et al., 1988). The authors suggest that the beneficial effect is due to inhibition of 
bone resorption associated with an increased secretion of calcitonin. 
A trial of 50 women aged over 75 years and "physical frailty", of which 90% were osteopenic 
or osteoporotic, who received 9 months of CEE 0.625 mg/day, showed an increase in 
lumbar spine BMD of 4, 3% (Villareal et al., 2001). The increase was 1.7% in total hip and 
2.3% in trochanter 2.3%, these results being similar to those observed in previous studies. 
4. Fracture prevention and HRT 
Randomized, case control and cohort studies indicate a potential effect of HRT in the 
prevention of vertebral, hip and forearm fractures in osteoporotic populations. 
A cohort study (Cauley et al., 1995) conducted in 9706 women aged over 65 years, and whose 
main objective was the evaluation of appendicular bone fractures in women treated with HRT, 
showed that current users who started treatment within 5 years after menopause decreased 
the risk of wrist fractures (RR = 0.39, 95% CI = 0.24 to 0.64), hip fractures (RR = 0.60, 95% CI = 
0.36 to 1.02) and other nonvertebral fractures (RR = 0.66, 95% CI = 0.54 to 0.80) when compared 
with nonusers of estrogen. HRT is more effective in reducing fracture risk if you start the five 
years following menopause, and if their use continues for more than 10 years. 
A randomized controlled trial of 4 years of follow up in 464 recently menopausal women 
(Komulainen et al., 1998), treated with 2 mg estradiol valerate and 1 mg cyproterone acetate 
daily, demonstrated a reduction in risk with RR 0.29 (0.10 to 0.90 CI). 
A meta-analysis (Grady et al., 1992) concluded that there is a 25% reduction in risk of hip 
fracture in postmenopausal women who used HRT. Subsequently, other published meta-
analysis (Torgerson & Bell-Syer, 2001) finds that the use of estrogen alone or combined with 
progestin for at least one year reduces the risk of nonvertebral fracture (RR 0.73, 95% CI: 0.56 
-0.94, P = 0.02). In women over 60 years, the effect was less marked (RR 0.88, 95% CI 0.71 to 
1.08, p = 0.22). 
In women with established osteoporosis (one or more prior vertebral fractures) has also 
shown a positive effect of HRT in preventing fractures. In a randomized study (Gonnelli et 
al., 1997), double-blind, placebo-controlled trial conducted in 75 women who were given 
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treatment with 0.1 mg of 17-beta-estradiol transdermal and oral medroxyprogesterone 
acetate, 11 days per month, analyzing the BMD, markers of bone turnover and 
histomorphometric study of iliac crest biopsy, demonstrated a positive effect of estrogen on 
the parameters analyzed resulting in a reduction given the frequency of vertebral fracture in 
the treated group versus placebo (RR = 0.39, 95% CI = 0.16-0.95). It can be infered that the 
number needed to treat (NNT) is 7 women/year to reduce vertebral fracture. 
However, other studies have shown no differences between the treatment groups and placebo. 
The Heart and Estrogen/Progestin Replacement Study (HERS) included 584 women with 
coronary disease, with an age range of 44-79 years who were treated with 0.625 mg/day CEE 
and 2.5 mg/day medroxyprogesterone acetate were compared with a placebo group in a 
follow-up period of 45 months. In this study, there was no beneficial effect of treatment 
compared with placebo in hip fracture rates or overall rates of fracture in such women not 
selected for risk factors for osteoporosis and had a low risk of osteoporosis. After 3 years, they 
published another analysis of these data, reaching the same results (Cauley et al., 2001). 
A review of 57 prospective cohort and retrospective case-control studies noted the limited 
evidence to confirm the anti-fracture efficacy in women who are on hormone replacement 
therapy (Reginster et al., 2000). Another review (Beral et al., 2002) of 4 randomized studies 
that included 20,000 women followed an average of 4.9 years, estimated a reduction of 
fractured neck of femur in 17/1000 users aged 50-59 years, this reduction rising to 5.5/1000 
in older women, 60-69 years. 
The highest level of evidence on the effect of HRT on fracture was obtained from the 
Women's Health Initiative (WHI) (Rossouw et al., 2002), This study was carried out in order 
to assess the main risks and benefits of the combined hormone preparation most commonly 
used in the United States, 0.625 mg CEE plus 2.5 mg of medroxyprogesterone acetate to 
health of postmenopausal women. The study included 8506 women in the treatment group 
and 8102 in the placebo group, with a follow-up time of 5.2 years. This study (The WHI 
Steering Committee, 2004) shows unequivocally that estrogen with or without progesterone 
reduce the risk of hip fracture, vertebral and other fractures, the only treatment that has 
demonstrated this effect in osteoporotic woman, regardless personal risk for fracture. 
The reduction observed was similar to that reported in previous observational studies and 
meta-analysis. The results in terms of fractures indicated that estrogen alone or in 
combination with progestin reduces the rate of hip fractures and clinical vertebral fractures 
by one third compared with placebo. Reductions in other osteoporotic fractures and total 
fractures were also statistically significant. 
All types of therapy, route of application and guidelines-beneficial as indicated in the results 
of a prospective cohort study with more than one million women (Million Women Study 
Collaborators, 2003), HRT users had significantly more low risk of fracture than nonusers 
(RR = 0.62, 95% CI = 0.58-0.66). 
A meta-analysis (Wells et al., 2002) indicates that BMD measurements are similar when 
comparing studies of prevention or treatment, estrogen alone or estrogen plus progestin, 
transdermal or oral, and different types of progestins. The duration and doses of treatment 
affect the dose effect on BMD. 
HRT has a tendency to reduce the risk of vertebral (RR = 0.66, 95% CI = 0.411 to 0.7) and 
non-vertebral fracture (RR = 0.87, 95% CI = 0.711 to 0.8). The protection against fractures 
require longer use of HRT. Cross-sectional studies indicate that for hip fracture prevention. 
Treatment duration should be between 5 and 10 years (Kiel et al., 1987). Swedish Hip 
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Fracture In Study, a case-control study (Michaëlsson, 1998) on 1327 women aged 50-81 years 
who had suffered a hip fracture and 3262 controls, current users of HRT have a substantial 
decrease in fracture risk compared to older users. The RR of hip fracture was 0.35 (95% CI = 
0.24 to 0.53) versus 0.76 (95% CI = 0.57 to 1.01). These data indicate that HRT is effective 
after menopause to maintain protection against fracture but only recent use was associated 
with optimal protection, since after 5 years without the protective effect of HRT use drops 
significantly. The beneficial effect is displayed even when treatment is started long after 
menopause. Thus, in current users, the initiation of therapy nine or more years after 
menopause provides a reduced risk of hip fracture are equivalent to those women who 
started early after menopause but who discontinued treatment. 
5. Tibolone 
Tibolone is a synthetic steroid derived from 19-nortestosterone, structurally similar to 
norestinone and noretinodrel, first generation nor-derived progestagens. It is described as a 
selective tissue estrogenic activity regulator (STEAR) because it has specific effects in 
different tissues after conversion to three active metabolites following oral ingestion 
(Kenemans, 2004). It has estrogenic, progestogenic and androgenic effects. Estrogenic 
metabolites act centrally, on the vagina and other tissues and, together with androgenic 
metabolites, relieve hot flushes and improve energy and sexual well-being (Nathorst-
Booszz, & Hammar, 1997; Nijland et al., 2008). On bone, tibolone has estrogenic effect acting 
on the estrogenic receptor (Modelska & Cummings, 2002). 
5.1 Effects on bone 
Preclinical studies indicate that tibolone prevents bone loss (axial and appendicular), caused 
by oophorectomy or low calcium intake in both young and mature rats and in rats with 
established osteopenia (Yoshitake et al, 1999). Experimental data conclude that tibolone is as 
effective as estrogen to prevent bone loss secondary to the decline of ovarian function, 
observed even in osteopenic rats an increase in BMD and femoral and vertebral bone 
strength, similar to estrogen (Berning et al., 2001). 
In humans, the action of tibolone on the skeletal system is also largely mediated by estrogen 
receptor binding and stimulation of it by some of its metabolites. 
5.2 Tibolone and bone turnover markers 
In general, studies show that tibolone decreases bone turnover (decrease in the formation 
and resorption) similar to that obtained with both estrogen in postmenopausal women with 
normal BMD and in the osteoporotic patient and, returning the process of turnover the 
existing levels in premenopausal women (Moore, 1999). 
Analyzing the effect of tibolone on BMD, it is shown to be capable of inhibiting the decrease 
and increase BMD compared with placebo or untreated control in both spontaneous and 
surgical menopause. Like estrogen, we analyzed the results of the use of low doses of 
tibolone. Low doses of 1.25 mg/day have an effect on the spine and hip similar to that found 
with standard doses of 2.5 mg/day, in elderly women and women younger postmenopausal 
(Gallagher et al., 2001). It has proven effective in maintaining BMD in menopausal women 
at standard doses. 
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5.3 Tibolone and prevention of fractures 
Tibolone (1.25 and 2.5 mg, respectively) increased lumbar and hip bone mineral density to a 
significantly greater extent than placebo in women with and without osteoporosis 
(Kenemans et al., 2009), as it was shown with a dose of 1.25 mg/day compared with 
raloxifene in a study of older osteopenic women (mean age 66 years) (Delmas et al., 2008). 
The lower dose also reduced the risk of vertebral and non-vertebral fractures in older 
osteoporotic women (mean age 68.3 years) in the LIFT study (Cummings et al., 2008). 
The data described about tibolone, in both experimental and clinical studies about the 
turnover markers and BMD, tibolone is similar to estrogen, and considering its relationship 
to fractures, it is conceivable that tibolone may have a similar effect on them. 
To understand the effects of tibolone on the incidence rate of new vertebral fractures in 
postmenopausal osteoporotic women began the Long-term Intervention on Fractures with 
Tibolone (LIFT) (Cummings, 2006), a multinational, double-blind trial, including 4000 women 
with tibolone versus placebo with calcium and a duration of 3-5 years. This study indicates the 
beneficial effect of tibolone on vertebral fractures (RR = 0.59) but has been discontinued by the 
increased risk of ischemic and hemorrhagic stroke (RR = 2.3 after 2.75 years). 
In a randomized, double-blind, placebo-controlled clinical trial (Cummings et al., 2008), they 
examined the effect of 1.25 mg of tibolone daily on the risk of vertebral and clinical fractures 
after 3 years and planned to assess the risks of breast cancer, cardiovascular disease, and 
endometrial cancer after 5 years. During a median of 34 months of treatment, the tibolone 
group, as compared with the placebo group, had a decreased risk of vertebral fracture, with 
70 cases versus 126 cases per 1000 person-years (relative hazard, 0.55; 95% CI, 0.41 to 0.74; p 
< 0.001), and a decreased risk of nonvertebral fracture, with 122 cases versus 166 cases per 
1000 person-years (relative hazard, 0.74; 95% CI, 0.58 to 0.93; p = 0.01).  
5.4 Adverse effects of tibolone 
The results of the LIFT study (Cummings et al., 2008) showed that the tibolone group also 
had a decreased risk of invasive breast cancer (relative hazard, 0.32; 95% CI, 0.13 to 0.80; p = 
0.02) and colon cancer (relative hazard, 0.31; 95% CI, 0.10 to 0.96; p = 0.04). However, the 
tibolone group had an increased risk of stroke (relative hazard, 2.19; 95% CI, 1.14 to 4.23; p = 
0.02), for which the study was stopped in February 2006 at the recommendation of the data 
and safety monitoring board. There were no significant differences in the risk of either 
coronary heart disease or venous thromboembolism between the two groups. 
6. Conclusions 
HRT produce increases in BMD at all skeletal sites. The reduction in fracture risk has been 
documented by data from a meta-analysis, cohort studies and the WHI study. 
Estrogen is a therapeutic option for the prevention and treatment of osteoporosis especially 
in women with postmenopausal symptoms, with consideration of their long-term use 
increases the risk. 
Therefore, treatment should be individualized by assessing the potential personal risks 
associated with therapy against the expected benefits. In this way, the patient will maintain 
continuity in the treatment, and will get the benefit sought in the bone. 
Tibolone is as effective as hormone replacement therapy (HRT) in treating symptoms and 
preventing bone loss, and it improves sexuality. It reduces bone turnover and improves 
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BMD, specially in trabecular bone. Published studies include few patients and have a short 
duration. Several large, randomized trials have since yielded additional data on tibolone’s 
efficacy and safety profile. 
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Prevention of osteoporosis starts in young ages and continues during aging in order to prevent fractures
associated with impaired quality of life, physical decline, mortality, and high cost for the health system. A
number of different specialties are holding the scientific knowledge in osteoporosis. For this reason, we have
collected papers from scientific departments all over the world for this book. The book includes up-to-date
information about basics of bones, epidemiological data, diagnosis and assessment of osteoporosis,
secondary osteoporosis, pediatric issues, prevention and treatment strategies, and research papers from
osteoporotic fields.
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